References
1. Ho MH, Wong WH, Heine RG, et al. Early clinical predictors of remission of peanut allergy in children.J Allergy Clin Immunol . 2008;121 (3):731-6.
2. Skolnick HS, Conover-Walker MK, Koerner CB, et al. The natural history of peanut allergy. J Allergy Clin Immunol . 2001;107 (2):367-74.
3. Bock SA, Atkins FM. The natural history of peanut allergy. J Allergy Clin Immunol . 1989;83 :900-4
4. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med . 1992;327 (6):380-4.
5. Baldwin M, Spong A, Doward L, et al. Patient-reported outcomes, patient-reported information: from randomized controlled trials to the social web and beyond.Patient . 2011;4 (1):11-7.
6. Haslam A, Herrera-Perez D, Gill J, et al. Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. JAMA Netw Open . 2020;3 (3):e200363.
7. Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet . 2019;394 (10207):1437-49.
8. Syed A, Garcia MA, Lyu SC, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol . 2014;133 (2):500-10.
9. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet . 2019;393 (10187):2222-32.
10. Tang ML, Ponsonby AL, Orsini F, et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. J Allergy Clin Immunol . 2015;135 (3):737-44 e8.
11. Hsiao K-C, Ponsonby A-L, Axelrad C, et al. Long-term clinical and immunological effects of Probiotic and Peanut Oral Immunotherapy (PPOIT) post-treatment cessation: Four-year follow-up of a randomized double-blind placebo-controlled trial.Lancet Child Adolesc Health . 2017;1 (2):97-105.
12. Dunn Galvin A, McMahon S, Ponsonby AL, et al. The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life. Allergy . 2018;73 (3):560-8.
13. DunnGalvin A, de BlokFlokstra BM, Burks AW, et al. Food allergy QoL questionnaire for children aged 0-12 years: content, construct, and cross-cultural validity. Clin Exp Allergy . 2008;38 (6):977-86.
14. Van der Velde JL, Flokstra-de Blok BM, Vlieg-Boerstra BJ, et al. Development, validity and reliability of the food allergy independent measure (FAIM). Allergy . 2010;65 (5):630-5.
15. Echeverría-Zudaire L, Fernández-Fernández S, Rayo-Fernández A, et al. Primary eosinophilic gastrointestinal disorders in children who have received food oral immunotherapy. Allergol Immunopathol . 2016;44 (6):531-6.
16. Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy, Asthma Immunol . 2014;113 (6):624-9.
17. Petroni D, Spergel JM. Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy. Ann Allergy, Asthma Immunol . 2018;120 (3):237-40.
18. Vickery BP, Scurlock AM, Kulis M, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol . 2014;133 (2):468-75.
19. Vickery BP, Vereda A, Casale TB, et al. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med. 2018;379 (21):1991-2001.
20. Virkud YV, Burks AW, Steele PH, et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol . 2017;139 (3):882-8.
21. Miettinen M, Matikainen S, Vuopio-Varkila J, et al. Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Infect Immun . 1998;66 (12):6058-62.
22. Pessi T, Sutas Y, Hurme M, et al. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy.2000;30 (12):1804-8.
23. Rautava S, Arvilommi H, Isolauri E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res . 2006;60 (2):221-4.
24. Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol . 2015;135 (5):1275-82.e1-6.
25. Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol . 2009;124 (2):292-300, .e1-97.